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Pancreatic tumours are scirrhous, avascular tumours, suggesting that they may produce angiogenesis inhibitors that suppress the
growth of the vasculature to the tumour and metastases. We have sought evidence for the angiogenesis inhibitor, endostatin, in
normal and cancerous pancreatic tissue. Using Western blotting, we found mature 20kDa endostatin in cancer tissue but not in
normal tissue. Several endostatin-related peptides of higher mol wt were present in both tissues. Extracts from normal tissue were
able to degrade exogenous endostatin, whereas extracts from cancer were without effect. Although the exocrine pancreas secretes
inactive proenzymes of trypsin, chymotrypsin and elastase, their possible role in this degradation was examined. The trypsin/
chymotrypsin inhibitor, Glycine max, did not prevent the degradation of endostatin by normal pancreatic extracts but elastatinal, a
specific inhibitor of elastase, reduced the rate of degradation. Extracts of pancreatic tumours did not express any detectable elastase
activity, but an elastase (Km 1.1mM) was expressed by extracts of normal pancreas. We conclude that endostatin is present and stable
in pancreatic cancer tissues, which may explain their avascular nature, but that normal pancreatic tissue expresses enzymes, including
elastase, which rapidly degrade endostatin. The stability of endostatin may have implications for its therapeutic use.
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Pancreatic cancer is the fifth leading cause of cancer death in the
UK, and despite advances in diagnosis, surgery and adjuvant
chemotherapy, the prognosis remains poor (Bramhall et al, 1995;
Jolly et al, 2002). Alternative methods of treatment therefore need
to be investigated. Evidence exists that growth and resultant
prognosis of pancreatic tumours is dependent upon microvessel
density (Ellis et al, 1998). New capillaries sprout from existing
blood vessels by a process known as angiogenesis. After
adolescence, angiogenesis normally only occurs during reproduc-
tion, wound healing and states of chronic inflammation. It is a
prerequisite for tumour growth and metastasis because without a
sufficient blood supply, tumours rarely grow beyond a few
millimetres in diameter (Folkman, 1990).
Angiogenesis is dependent upon both pro- and antiangiogenic
factors (Folkman and Klagsbrun, 1987). One such antiangiogenic
factor is endostatin. Endostatin is a 20kDa fragment of the
noncollagenous (NC-1) C-terminus of the basement membrane
protein, collagen XVIII. Endostatin specifically inhibits endothelial
cell migration, and induces cell cycle arrest and apoptosis in vitro,
and in vivo, it reduces tumour growth (O’Reilly et al, 1997).
Endostatin is now in clinical trials as an anticancer chemother-
apeutic agent. Since collagen XVIII is a component of the vascular
basement membrane, endostatin and endostatin-related proteins
have been found in a variety of tissues (Saarela et al, 1998; Miosge
et al, 1999). The occurrence of a broad range of endostatin-like
fragments in tissues and serum suggests that collagen XVIII is
sensitive to degradation at a number of sites by proteases
(Standker et al, 1997; Sasaki et al, 1998; John et al, 1999; Ferreras
et al, 2000).
Pancreatic tumours are scirrhous, avascular tumours, which
suggests that the primary pancreatic tumour may produce an
angiogenesis inhibitor, which suppresses the growth of the
vasculature to the tumour and of metastases. Following surgical
resection, removal of this angiogenesis inhibitor would result in
removal of an inhibitory force acting upon the dormant
micrometastases as elaborated by several authors (Folkman,
1990, 1995; Kirsch et al, 2000, 2004). The normal exocrine
pancreas produces large amounts of proforms of the proteolytic
enzymes trypsin, chymotrypsin and elastase, which are destined
for the gastrointestinal tract. We hypothesised that pancreatic
tissue contains collagen XVIII, and is therefore capable of
producing endostatin from its precursor by proteolytic action of
activated forms of these proteases or other proteases synthesised
by the pancreas.
Evidence for the expression of collagen XVIII and endostatin in
samples of both normal pancreatic tissue and pancreatic cancer
was therefore sought. The regulation of endostatin production was
investigated by studying endogenous protease action upon
collagen XVIII and exogenous endostatin.
METHODS AND MATERIALS
Preparation of tissue lysates
Tissue samples were obtained at surgery and were frozen within
10min of removal. Ethical approval was obtained for all tissue
used. At all times, the tissue and the homogenates derived from the
Received 30 April 2004; revised 14 September 2004; accepted 28
September 2004; published online 16 November 2004
*Correspondence: Dr MC Eggo, The Medical School, University of
Birmingham, Birmingham B15 2TT, UK; E-mail M.C.Eggo@bham.ac.uk
British Journal of Cancer (2005) 92, 89–93
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
stissues were kept in an ice bath at 01C to prevent warming and
potential proteolysis. Approximately 1cm
3 sections of frozen
normal pancreatic and pancreatic cancer tissue (n¼5) were
homogenised in 2ml of Hank’s balanced salt solution (HBSS)
using a motorised homogeniser (Polytron). The homogenate was
sonicated using five pulses of 30s each and centrifuged at 15000g
for 30min. The supernatant was removed and stored at  201C
until use. In experiments examining expression of endostatin in
tumour and normal tissues, 0.1% Triton X-100 was included to aid
solubilisation from membranes. The pelleted, insoluble material
was dissolved by boiling in 2% sodium dodecyl sulphate (SDS) in
HBSS and stored at  201C until use.
Western blotting
A volume containing 100mg of protein was used and samples were
heated to 601C for 30min in reducing sample buffer containing
100mM 2-mercaptoethanol, 2% SDS and 62.5mM Tris-HCl pH 6.8
before loading onto 12.5% SDS-polyacrylamide gels. Western
blotting was performed as described previously using PVDF
membrane (Hybond P, Amersham Pharmacia) (Michell et al,
1997). Primary antibody raised in rabbit to endostatin (Chemicon,
1:100 dilution) and horseradish peroxidase-labelled secondary
antibodies (Santa-Cruz Ltd, 1:50000 dilution) were used with
enhanced chemiluminescence detection (ECL). The specificity of
the endostatin primary antibody was confirmed by preabsorption
to recombinant endostatin. No proteins were identified by ECL
when the primary antibody was saturated with recombinant
endostatin (data not shown).
Stability of endostatin in normal pancreatic tissue and
pancreatic cancer tissue
Aliquots of homogenates prepared in HBSS containing 100mgo f
normal or cancer tissue proteins were incubated at 371C with 5ng
of recombinant endostatin (CN Bioscience) for periods of up to
20h. Incubation was terminated at various time points by
immersing the samples in an ice bath and adding reducing sample
buffer. To test the thermal sensitivity of the reaction, 100mgo f
HBSS-soluble normal pancreatic extract was denatured by boiling
and incubated with endostatin in the manner above. Analysis by
Western immunoblotting was performed.
Effect of protease inhibitors on stability of endostatin in
tissue lysates
In total, 5ng of endostatin was incubated for varying times up to
24h at 371C with HBSS-soluble pancreatic homogenate in the
presence of either a combined trypsin–chymotrypsin inhibitor
from Glycine max (soybean) (Sigma), at a concentration of 100mg
inhibitor per 100mg total protein, or Elastatinal (Calbiochem,
Germany), a specific, irreversible elastase inhibitor, at a concen-
tration of 100mM.
Elastase activity in normal and pancreatic cancer tissue
Activity of elastase in the pancreatic tissue lysate was evaluated
with a colorimetric assay using N-methoxysuccinyl-Ala-Ala-Pro-
Val P-nitroanilide as a chromogenic substrate as described by
Bieth and Wermuth (1973). The molar extinction coefficient of the
product formed was 8800, read at 410nm in a 1cm light path.
Incubation was performed at room temperature on a 96-well
microplate and the plate was read at intervals between 5 and
30min up to a period of 24h. The kinetics of the HBSS-soluble
pancreatic tissue homogenates was evaluated and the assay was
verified using purified neutrophil elastase (Sigma, UK). The results
were analysed by plotting a Lineweaver–Burk curve to determine
Km and Vmax.
All experiments were performed in triplicate to confirm
reproducibility.
RESULTS
Presence of collagen XVIII-endostatin in normal and
cancerous pancreatic tissues
Figure 1 shows a Western blot of extracts of proteins in the soluble
fraction and the SDS-solubilised material from normal and
cancerous pancreatic tissue, probed for endostatin. Immunoreac-
tive bands are present at 120, 70, 36 and 20kDa. The larger bands
contain the endostatin fragment at their C terminus. The soluble
fraction contains collagen XVIII (120kDa), a 70kDa fragment and
the NC-1 fragment (36kDa) in both normal pancreatic and
pancreatic cancer tissue. The 20kDa form of mature endostatin
is present in the cancer tissue but not normal tissue. The SDS-
solubilised fraction contains the 36kDa fragment in both normal
and pancreatic cancer tissue.
Stability of exogenous endostatin in HBSS-soluble
fractions from normal and cancer-derived pancreatic
tissue
Recombinant endostatin was incubated with the HBSS-soluble
fraction from normal pancreatic tissue and its stability deter-
mined by Western blotting. Figure 2 shows its stability with
time. Degradation of collagen XVIII, endogenous endostatin-
related fragments (70 and 36kDa) and exogenous 20kDa
endostatin was seen at 2h with complete degradation occurring
by 4h. The immunoreactivity of the endogenous endostatin-
related fragment at 36kDa was seen to diminish at 0.5h and
then increase to a maximum intensity at 2h. This increase in
intensity coincided with the loss of the immunoreactivity of the
band at 70kDa.
The same experiment was repeated with HBSS-soluble
extracts from pancreatic cancer tissue and the results are shown
in Figure 3. Neither endogenous nor exogenous endostatin was
degraded over time. Degradation of collagen XVIII and endo-
statin-related fragments (70 and 36kDa) was not observed over a
4h time period.
Heat treatment of the HBSS-soluble normal pancreatic extract
by boiling prevented the degradation of endogenous endostatin-
related fragments and exogenous 20kDa endostatin (data not
shown).
20 kDa 
36 kDa  
70 kDa 
 N     C N C
 HBSS-soluble SDS-soluble
120 kDa
Figure 1 Western immunoblotting demonstrating the presence of
endostatin-immunoreactive fragments in HBSS-soluble and SDS-soluble
extracts from normal and cancer pancreas (N – normal pancreas, C –
cancer pancreas).
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HBSS-soluble extracts of pancreatic tissue
To assess the potential contribution of endogenous pancreatic
proteases, trypsin and chymotrypsin, to the degradation of
exogenous endostatin, we performed the same experiment
described in Figure 2 in the presence of a trypsin–chymotrypsin
inhibitor in excess. When endostatin was incubated with HBSS-
soluble extract from normal pancreatic tissue and the inhibitor, its
degradation was not prevented (Figure 4A). By 4h, all immunor-
eactive endostatin added to the sample had disappeared. The
effects in Figure 2 were therefore unlikely to be due to the presence
of endogenous active trypsin and chymotrypsin.
The effects of the elastase inhibitor, elastatinal, on the
degradation of exogenous endostatin by an HBSS-soluble extract
from normal pancreatic tissue are shown in Figure 4B. In the
absence of elastase inhibitor, complete degradation of endostatin
was seen by 4h. In the samples with elastase inhibitor added (bold-
type arrows), endostatin remained un-degraded at 4h. By 20h,
when the experiment was terminated, endostatin had however
been degraded.
Elastase activity in extracts from normal and cancerous
pancreatic extracts
Elastase activity, evaluated using the colorimetric assay described,
is demonstrated for normal and pancreatic cancer tissue in
Figure 5. There was a significant accumulation of product formed
with time by the HBSS-soluble normal pancreatic tissue homo-
genate. In contrast, the pancreatic cancer tissue HBSS-soluble
homogenate did not show any detectable product.
Km for the reaction was calculated to be 1.1mM using a
Lineweaver–Burk plot of 1/rate vs 1/substrate concentration. The
slope is Km/V, the y intercept is 1/V and the x intercept is  1/Km.
DISCUSSION
Using Western immunoblotting we found that mature 20kDa
endostatin is present in pancreatic cancer tissue. Endostatin-
related fragments and collagen XVIII were also present in normal
pancreatic tissues but mature 20kDa endostatin was not detected.
Collagen XVIII and the NC-1 fragments, but not endostatin, were
found in the SDS-soluble fractions from both tissues and we
conclude that they are not totally soluble in HBSS, consistent with
membrane localisation. Whether these endostatin-related frag-
ments have any biological activity is unknown; however, their
20 kDa
70 kDa
120 kDa
   x  0    0.25  0.5 1    1.5      2   3     4   20
Time (h)
36 kDa
Figure 2 Western immunoblotting demonstrating that normal HBSS-
soluble pancreatic homogenate degrades exogenous recombinant endo-
statin over time. A fixed amount of HBSS-soluble extract from normal
pancreas was incubated with 5ng of recombinant endostatin for the time
periods shown. Recombinant endostatin migrates as a single band of
20kDa. Sample x is the normal pancreatic homogenate without exogenous
endostatin.
70 kDa
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36 kDa
20 kDa
  0  4   0
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+
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Figure 3 Western immunoblotting demonstrating that an HBSS-soluble
extract from pancreatic cancer tissues does not degrade exogenous
recombinant endostatin over 4h. Exogenous endostatin (5ng) was added
to the samples in the lanes marked þ.
0 0.5 1     2 3  4  20 
Time (h) 
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Figure 4 (A) Western immunoblotting demonstrating the effect of a chymotrypsin–trypsin inhibitor upon degradation of exogenous endostatin (5ng)
with time by normal pancreatic homogenates. (B) Western immunoblotting demonstrating the effect of the elastase inhibitor, elastatinal (10
 4 M), on
degradation of exogenous endostatin by normal pancreatic homogenates. Equal quantities of HBSS-soluble extracts of normal pancreatic tissue were
incubated with 5ng recombinant endostatin and in the absence or presence (marked
þ and arrowed) of elastatinal for the indicated times.
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role as does the fact that fragments of the structurally related
collagen XV inhibit angiogenesis (Marneros and Olsen, 2001;
Sasaki et al, 2002).
One explanation for the absence of endostatin in normal
pancreatic tissue is that endogenous endostatin can be degraded
by pancreatic proteases released during the homogenisation
process. We demonstrated, using exogenous endostatin, that the
normal pancreas contains enzymatic activity capable of degrading
both exogenous mature 20kDa endostatin and endogenous
collagen XVIII and endostatin-related fragments. Boiling the
normal pancreatic tissue extract prevented degradation of
exogenous endostatin, consistent with proteolytic action. We also
assayed whether varying concentrations of pancreatic cancer
extract could inhibit the degradation of endostatin by normal
pancreatic tissue but found no inhibition (data not shown)
indicating that the effects of pancreatic cancer tissue were not
due to the synthesis of a protease inhibitor.
Trypsin–chymotrypsin inhibition had no effect upon the ability
of normal pancreas to degrade exogenous endostatin. This
suggests that these enzymes are either not present or remain in
their inactive proforms. Our studies show that elastase inhibition
partially prevents endostatin degradation. Pancreatic elastase
secreted into the GI tract is a protease of broad specificity and is
activated in the duodenum by trypsin. We determined Km and
Vmax for the elastase activity in the HBSS-soluble extracts. Km was
1.1mM, which compares with a reported Km of 6.2mM for porcine
pancreatic elastase and 0.14mM for human leukocyte elastase
(Castillo et al, 1979). Whether the elastase that degrades endostatin
is the elastase secreted into the GI tract remains unclear at present.
It is certainly possible that it is a different elastase. Our data
also suggest that HBSS-soluble pancreatic tissue homogenates
contain other proteases capable of acting alone or in concert
with elastase to degrade endostatin. Ferreras et al (2000)
demonstrated that cathepsins L, B, K and D were also capable of
degrading endostatin.
In contrast to normal pancreatic tissue, elastase activity was not
detectable in pancreatic cancer tissue homogenates, which may
explain both why mature 20kDa endostatin is present in
pancreatic cancer tissue and why exogenous endostatin is not
degraded by pancreatic cancer homogenates. Since endostatin-
related fragments were present in both normal and cancer tissues,
elastase would appear to be more important in endostatin
degradation than in its production.
Endostatin and endostatin-related fragments have been found in
a number of tissues, which is not surprising since collagen XVIII is
known to be a structural component of blood vessel walls.
Endostatin release will result in a disturbance in the balance
between angiogenesis promotion and inhibition, at a local level
within the existing vasculature. Endostatin is known to regulate
endothelial cell adhesion, survival and migration (Sasaki et al,
1998; Dhanabal et al, 1999). Conceivably following cellular injury,
cellular proteases are released, which may degrade collagen XVIII
completely with only transient or no production of endostatin. In
this state, proangiogenic factors remain in the ascendancy and
angiogenesis would result. In the absence of cellular injury and
death, proteases capable of degrading endostatin are reduced and
local levels of endostatin begin to rise again, restoring the balance
between pro- and antiangiogenic factors. We hypothesise that
endostatin is produced by proteolytic degradation of collagen
XVIII in the normal population at a baseline level and is regulated
by protease action rather than being produced in bursts when the
body needs to reduce angiogenesis.
In cases of malignancy, in order for metastasis to occur, the
balance of angiogenic factors must be biased in favour of
proangiogenic factors and in favour of invasion, mediated through
proteases. Pancreatic tumour cell lines are known to produce a
plethora of proteases (Kitamura et al, 2000) and unusually to
express receptors for angiogenic growth factors of the VEGF family
(Itakura et al, 2000). Endostatin may work by inhibiting the
mitogenic effects of these growth factors on the tumour cells as
well as the endothelial cells (Kim et al, 2002). If tumour cells
produce proteases capable of releasing endostatin from collagen
XVIII, or angiostatin from plasminogen (O’Mahony et al, 1998)
but do not produce proteases that are capable of degrading these
antiangiogenic factors, then the tumour may be invasive but
angiogenesis and metastases will be limited. In our experiments,
tissue samples had been obtained from patients in whom
metastasis had not occurred and it could be argued that this was
because of the presence of endostatin.
We showed that elastase activity was undetectable in pancreatic
cancer tissue, which is the likely explanation for why endostatin
was not broken down. Patients with pancreatic tumours frequently
have elevated circulating immunoreactive elastase Hayakawa et al
(1990) but because higher levels are associated with a better
prognosis, we suggest that this is a marker of the differentiation of
the tumour. This circulating elastase is likely to be the inactive
proform of pancreatic elastase, which would not thus degrade
endostatin. Conversely, pancreatic tumours expressing macro-
phage metalloelastase have a worse prognosis than those that do
not (Balaz et al, 2002). In this instance, we suggest that the elastase
is active and degrades endostatin so that angiogenesis can occur as
well as promoting invasion.
Folkman popularised the concept that surgical removal of
tumours might remove a source of antiangiogenic factors and
influence tumour biology by allowing metastatic disease to grow
(Folkman, 1990, 1995). Our data support this by showing the
presence and the stability of endostatin in pancreatic tumours.
Tsunemi et al (2003) revealed progression of pulmonary
metastases and significantly decreased serum concentrations of
endostatin following removal of a primary osteosarcoma. What
biological advantage endostatin production gives to the primary
tumour is open to conjecture. Conceivably, there is a survival
benefit due to reduced exposure to immunosurveillance. Alter-
natively, endostatin production may be viewed as a host defence.
When the tumour secretes proteases to aid invasion, endostatin
production due to collagen XVIII expression in the matrix
would limit tumour spread. Only when the tumour can
produce proteases, which degrade antiangiogenic factors, can
metastases occur.
Normal 
Cancer
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Figure 5 Elastase assay for normal and pancreatic cancer homogenates.
HBSS-soluble extracts from normal and pancreatic cancer homogenates
were incubated with N-methoxysuccinyl-Ala-Ala-Pro-Val P-nitroanilide as a
chromogenic substrate as described by Bieth and Wermuth (1973).
Incubation was performed at room temperature on a 96-well microplate
and absorbance read at 410nm.
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thought. It is likely however, that to be most effective, extended
suppression of the angiogenic process is required. Since proteases
have been shown to be capable of degrading endostatin, both
in vitro and in vivo, delivery of endostatin as a chemothe-
rapeutic agent in the conventional sense may be difficult.
Consistent with this, recent data from a mouse tumour model
have shown that continuous intraperitoneal infusion is
more efficacious than intravenous bolus injections (Kisker
et al, 2001).
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